Selected research
Industry Research
Antibody-drug Conjugates for Tumors Industry Research Report 2026
Market perspective
The global Antibody-drug Conjugates for Tumors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Antibody-drug Conjugates for Tumors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Antibody-drug Conjugates for Tumors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Antibody-drug Conjugates for Tumors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Antibody-drug Conjugates for Tumors include Takeda, RemeGen, Roche（Genentech）, Rakuten Medical, Gilead Sciences, Pfizer（Seagen), GSK, Daiichi Sankyo and AbbVie(ImmunoGen), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Antibody-drug Conjugates for Tumors market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antibody-drug Conjugates for Tumors Market by Company
Takeda
RemeGen
Roche（Genentech）
Rakuten Medical
Gilead Sciences
Pfizer（Seagen)
GSK
Daiichi Sankyo
AbbVie(ImmunoGen)
AstraZeneca
ADC Therapeutics
Antibody-drug Conjugates for Tumors Segment by Type
DNA Damaging Drugs
Tubulin Inhibitors
Other
Antibody-drug Conjugates for Tumors Segment by Application
Hematological Tumors
Solid Tumors
Antibody-drug Conjugates for Tumors Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody-drug Conjugates for Tumors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antibody-drug Conjugates for Tumors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody-drug Conjugates for Tumors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Antibody-drug Conjugates for Tumors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Antibody-drug Conjugates for Tumors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Antibody-drug Conjugates for Tumors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- DNA Damaging Drugs
- Tubulin Inhibitors
- Other
Applications
- Hematological Tumors
- Solid Tumors
Companies covered
- Takeda
- RemeGen
- Roche（Genentech）
- Rakuten Medical
- Gilead Sciences
- Pfizer（Seagen)
- GSK
- Daiichi Sankyo
- AbbVie(ImmunoGen)
- AstraZeneca
- ADC Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Antibody-drug Conjugates for Tumors Market Size (2021-2032)
- 2.2.2 Global Antibody-drug Conjugates for Tumors Sales (2021-2032)
- 2.2.3 Global Antibody-drug Conjugates for Tumors Market Average Price (2021-2032)
- 2.3 Antibody-drug Conjugates for Tumors by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 DNA Damaging Drugs
- 2.3.3 Tubulin Inhibitors
- 2.3.4 Other
- 2.4 Antibody-drug Conjugates for Tumors by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hematological Tumors
- 2.4.3 Solid Tumors
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Antibody-drug Conjugates for Tumors Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Antibody-drug Conjugates for Tumors Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Antibody-drug Conjugates for Tumors Revenue of Manufacturers (2021-2026)
- 3.4 Global Antibody-drug Conjugates for Tumors Average Price by Manufacturers (2021-2026)
- 3.5 Global Antibody-drug Conjugates for Tumors Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Antibody-drug Conjugates for Tumors, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Antibody-drug Conjugates for Tumors, Product Type & Application
- 3.8 Global Manufacturers of Antibody-drug Conjugates for Tumors, Established Date
- 3.9 Global Antibody-drug Conjugates for Tumors Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Antibody-drug Conjugates for Tumors Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Antibody-drug Conjugates for Tumors Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 RemeGen
- 4.2.1 RemeGen Company Information
- 4.2.2 RemeGen Business Overview
- 4.2.3 RemeGen Antibody-drug Conjugates for Tumors Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 RemeGen Antibody-drug Conjugates for Tumors Product Portfolio
- 4.2.5 RemeGen Recent Developments
- 4.3 Roche（Genentech）
- 4.3.1 Roche（Genentech） Company Information
- 4.3.2 Roche（Genentech） Business Overview
- 4.3.3 Roche（Genentech） Antibody-drug Conjugates for Tumors Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Roche（Genentech） Antibody-drug Conjugates for Tumors Product Portfolio
- 4.3.5 Roche（Genentech） Recent Developments
- 4.4 Rakuten Medical
- 4.4.1 Rakuten Medical Company Information
- 4.4.2 Rakuten Medical Business Overview
- 4.4.3 Rakuten Medical Antibody-drug Conjugates for Tumors Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Rakuten Medical Antibody-drug Conjugates for Tumors Product Portfolio
- 4.4.5 Rakuten Medical Recent Developments
- 4.5 Gilead Sciences
- 4.5.1 Gilead Sciences Company Information
- 4.5.2 Gilead Sciences Business Overview
- 4.5.3 Gilead Sciences Antibody-drug Conjugates for Tumors Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Gilead Sciences Antibody-drug Conjugates for Tumors Product Portfolio
- 4.5.5 Gilead Sciences Recent Developments
- 4.6 Pfizer（Seagen)
- 4.6.1 Pfizer（Seagen) Company Information
- 4.6.2 Pfizer（Seagen) Business Overview
- 4.6.3 Pfizer（Seagen) Antibody-drug Conjugates for Tumors Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer（Seagen) Antibody-drug Conjugates for Tumors Product Portfolio
- 4.6.5 Pfizer（Seagen) Recent Developments
- 4.7 GSK
- 4.7.1 GSK Company Information
- 4.7.2 GSK Business Overview
- 4.7.3 GSK Antibody-drug Conjugates for Tumors Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 GSK Antibody-drug Conjugates for Tumors Product Portfolio
- 4.7.5 GSK Recent Developments
- 4.8 Daiichi Sankyo
- 4.8.1 Daiichi Sankyo Company Information
- 4.8.2 Daiichi Sankyo Business Overview
- 4.8.3 Daiichi Sankyo Antibody-drug Conjugates for Tumors Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Daiichi Sankyo Antibody-drug Conjugates for Tumors Product Portfolio
- 4.8.5 Daiichi Sankyo Recent Developments
- 4.9 AbbVie(ImmunoGen)
- 4.9.1 AbbVie(ImmunoGen) Company Information
- 4.9.2 AbbVie(ImmunoGen) Business Overview
- 4.9.3 AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Product Portfolio
- 4.9.5 AbbVie(ImmunoGen) Recent Developments
- 4.10 AstraZeneca
- 4.10.1 AstraZeneca Company Information
- 4.10.2 AstraZeneca Business Overview
- 4.10.3 AstraZeneca Antibody-drug Conjugates for Tumors Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AstraZeneca Antibody-drug Conjugates for Tumors Product Portfolio
- 4.10.5 AstraZeneca Recent Developments
- 4.11 ADC Therapeutics
- 4.11.1 ADC Therapeutics Company Information
- 4.11.2 ADC Therapeutics Business Overview
- 4.11.3 ADC Therapeutics Antibody-drug Conjugates for Tumors Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 ADC Therapeutics Antibody-drug Conjugates for Tumors Product Portfolio
- 4.11.5 ADC Therapeutics Recent Developments
5 Global Antibody-drug Conjugates for Tumors Market Scenario by Region
- 5.1 Global Antibody-drug Conjugates for Tumors Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Antibody-drug Conjugates for Tumors Sales by Region: 2021-2032
- 5.2.1 Global Antibody-drug Conjugates for Tumors Sales by Region: 2021-2026
- 5.2.2 Global Antibody-drug Conjugates for Tumors Sales by Region: 2027-2032
- 5.3 Global Antibody-drug Conjugates for Tumors Revenue by Region: 2021-2032
- 5.3.1 Global Antibody-drug Conjugates for Tumors Revenue by Region: 2021-2026
- 5.3.2 Global Antibody-drug Conjugates for Tumors Revenue by Region: 2027-2032
- 5.4 North America Antibody-drug Conjugates for Tumors Market Facts & Figures by Country
- 5.4.1 North America Antibody-drug Conjugates for Tumors Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Antibody-drug Conjugates for Tumors Sales by Country (2021-2032)
- 5.4.3 North America Antibody-drug Conjugates for Tumors Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Antibody-drug Conjugates for Tumors Market Facts & Figures by Country
- 5.5.1 Europe Antibody-drug Conjugates for Tumors Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Antibody-drug Conjugates for Tumors Sales by Country (2021-2032)
- 5.5.3 Europe Antibody-drug Conjugates for Tumors Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Antibody-drug Conjugates for Tumors Market Facts & Figures by Country
- 5.6.1 Asia Pacific Antibody-drug Conjugates for Tumors Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Antibody-drug Conjugates for Tumors Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Antibody-drug Conjugates for Tumors Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Antibody-drug Conjugates for Tumors Market Facts & Figures by Country
- 5.7.1 South America Antibody-drug Conjugates for Tumors Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Antibody-drug Conjugates for Tumors Sales by Country (2021-2032)
- 5.7.3 South America Antibody-drug Conjugates for Tumors Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Antibody-drug Conjugates for Tumors Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Antibody-drug Conjugates for Tumors Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Antibody-drug Conjugates for Tumors Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Antibody-drug Conjugates for Tumors Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Antibody-drug Conjugates for Tumors Sales by Type (2021-2032)
- 6.1.1 Global Antibody-drug Conjugates for Tumors Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2021-2032)
- 6.2 Global Antibody-drug Conjugates for Tumors Revenue by Type (2021-2032)
- 6.2.1 Global Antibody-drug Conjugates for Tumors Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2021-2032)
- 6.3 Global Antibody-drug Conjugates for Tumors Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Antibody-drug Conjugates for Tumors Sales by Application (2021-2032)
- 7.1.1 Global Antibody-drug Conjugates for Tumors Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2021-2032)
- 7.2 Global Antibody-drug Conjugates for Tumors Revenue by Application (2021-2032)
- 7.2.1 Global Antibody-drug Conjugates for Tumors Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2021-2032)
- 7.3 Global Antibody-drug Conjugates for Tumors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Antibody-drug Conjugates for Tumors Value Chain Analysis
- 8.1.1 Antibody-drug Conjugates for Tumors Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Antibody-drug Conjugates for Tumors Production Mode & Process
- 8.2 Antibody-drug Conjugates for Tumors Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Antibody-drug Conjugates for Tumors Distributors
- 8.2.3 Antibody-drug Conjugates for Tumors Customers
9 Global Antibody-drug Conjugates for Tumors Analyzing Market Dynamics
- 9.1 Antibody-drug Conjugates for Tumors Industry Trends
- 9.2 Antibody-drug Conjugates for Tumors Industry Drivers
- 9.3 Antibody-drug Conjugates for Tumors Industry Opportunities and Challenges
- 9.4 Antibody-drug Conjugates for Tumors Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst